Search Results
You are looking at 1-5 of 5
Article selection flowchart.
Skip to main content
Anthony Rengel,
Vienna Tran, and
Li Shean Toh
Article Category: Research Article
Volume/Issue: Volume 94: Issue 5
Online Publication Date: May 01, 2023
Page Range: 389 – 395
loss still occurs in the lumbar spine and femur.
38
–
40
Although exercise may be considered sufficient for short duration spaceflights, pharmacological countermeasures should be considered for longer spaceflights. To date, only alendronate has been assessed with a bed rest study
26
and clinical trial during spaceflight.
25
While demonstrating maintenance of bone density, the method of administration and common side-effects are an issue, with 2 out of 11 astronauts participating in the in-flight study withdrawing due to gastrointestinal side
Article Category: Research Article
Volume/Issue: Volume 83: Issue 9
Online Publication Date: Sep 01, 2012
Page Range: 914 – 915
Anthony Rengel,
Vienna Tran, and
Li Shean Toh
Fig. 1.
Lawrence W. Steinkraus
Article Category: Research Article
Volume/Issue: Volume 74: Issue 8
Online Publication Date: Aug 01, 2003
DOI:
Page Range: 869 – 873
John Caruso,
Neel Patel,
Joseph Wellwood, and
Lance Bollinger
Article Category: Review Article
Volume/Issue: Volume 94: Issue 12
Online Publication Date: Dec 01, 2023
Page Range: 923 – 933
the risk of kidney stones, by as much as 30–125 mg · day −1 as seen from 6-mo spaceflights.
31
Various combinations of bisphosphonate (alendronate at 70 mg · wk −1 ) and resistive exercise treatments to abate bone loss were studied on the ISS.
76
With data from three groups obtained before and after 6 mo of spaceflight, one group trained on the Interim Resistive Exercise Device, another on the advanced resistive exercise device (ARED), and a third combined ARED and bisphosphonate (70 mg · wk −1 ) treatments. Each group incurred significant losses